Top Midday Stories: Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks; Supreme Court Allows TikTok Ban to Take Effect

MT Newswires Live
18 Jan

Wall Street's major market averages were higher around midday Friday ahead of a long Martin Luther King, Jr. holiday weekend and the inauguration of President-elect Donald Trump.

In company news, Novo Nordisk (NVO) shares slid 4.8% after the Department of Health and Human Services said that the company's Ozempic, Wegovy and Rybelsus are among the 15 additional drugs selected for US Medicare price negotiations.

"Novo Nordisk remains opposed to government price setting through the [Inflation Reduction Act] and has significant concerns about how the law is being implemented by this administration," Novo Nordisk said in a statement emailed to MT Newswires.

The US Supreme Court will allow a ban on TikTok to take effect as scheduled on Sunday after rejecting an appeal on Friday.

Schlumberger (SLB) shares rose nearly 8% after it reported higher Q4 adjusted earnings and revenue and raised its quarterly dividend.

Truist Financial (TFC) shares climbed 4.8% after it reported higher Q4 adjusted earnings and total revenue.

Fastenal (FAST) shares added 2.3% after it said its Q4 net income was unchanged and net sales rose from a year earlier.

J.B. Hunt Transport Services (JBHT) shares retreated 6.9% in recent Friday trading after it reported Q4 earnings late Thursday of $1.53 per diluted share, which fell short of market expectations.

Price: 78.95, Change: -4.13, Percent Change: -4.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10